BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.32), in-line with the analyst estimate of ($0.32). Revenue for the quarter came in at $449.8 million versus the consensus estimate of $442.09 million.

GUIDANCE:

BioMarin Pharma sees FY2022 revenue of $2.05-2.15 billion, versus the consensus of $2.14 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.